Multiple System Atrophy

Overview

Multiple system atrophy (MSA) is a rare, adult-onset, rapidly progressive neurodegenerative disorder. It combines problems with automatic body functions—such as blood-pressure control, bladder function, breathing, and sleep—with Parkinson-like slowness and stiffness and/or cerebellar problems with balance, speech, and coordination. In MSA, the protein alpha-synuclein accumulates abnormally within oligodendrocytes, the brain cells that support and insulate nerve fibers. Symptoms usually begin in the 50s or 60s, and average survival is approximately 7–9 years from symptom onset. Practical guide to MSA

There is currently no approved treatment proven to slow, stop, reverse, or cure MSA. Standard care is multidisciplinary and symptom-directed: carefully selected levodopa may help some motor symptoms, while blood-pressure medicines and lifestyle measures, bladder care, physiotherapy, speech and swallowing support, respiratory and sleep management, nutrition, mobility equipment, and palliative care address the disease’s many effects. Symptomatic care in MSA

Scope of Recent Research (2020–present)

Research since 2020 has become more biologically focused and clinically ambitious, centering on removal or prevention of toxic alpha-synuclein, correction of iron-related oxidative injury, protection of glia and myelin, inflammation control, and earlier, more accurate diagnosis for trials. The field now includes completed phase 2 studies, an active phase 3 antibody trial, biomarker platforms, and early cell-therapy studies; however, no approach has yet demonstrated the durable, objective evidence needed to support a curative therapy. AMULET amlenetug trial MASCOT phase 3 trial

Major Breakthroughs and Emerging Therapies

The most advanced disease-targeting strategy is alpha-synuclein immunotherapy. Amlenetug (Lu AF82422) is an intravenous monoclonal antibody designed to bind extracellular alpha-synuclein and potentially reduce its movement between cells. In the 64-person randomized phase 2 AMULET trial, the prespecified primary endpoint was not met, but the analysis estimated a non-significant 19% slowing of clinical progression and found generally comparable adverse-event and serious-adverse-event rates between treatment and placebo groups. Those results were sufficient for Lundbeck to advance amlenetug into the larger MASCOT phase 3 trial rather than establish efficacy. AMULET amlenetug trial MASCOT phase 3 trial

A second strategy addresses the interaction between excess brain iron, oxidative stress, and alpha-synuclein aggregation. ATH434 is an oral “iron chaperone” intended to redistribute loosely bound iron rather than simply remove all iron from the brain. In an oligodendrocyte alpha-synuclein mouse model of MSA, ATH434 reduced iron-associated toxicity, reduced alpha-synuclein pathology, protected nerve cells, and improved motor performance. ATH434 in an MSA mouse model Its 77-participant placebo-controlled phase 2 trial has been completed, making it one of the more mature small-molecule MSA programs, although confirmatory clinical evidence remains necessary. ATH434 phase 2 trial

Drug repurposing has produced a cautionary but useful signal. Exenatide, a glucagon-like peptide-1 receptor agonist used for diabetes, was tested in a 50-person randomized, open-label phase 2a trial. At 48 weeks, the treated group had less worsening on the participant- and clinician-rated UMSARS scale, but objective mobility measures, imaging, neurofilament light chain, and cerebrospinal-fluid alpha-synuclein oligomer measures did not differ between groups. The investigators concluded that the discrepancy could reflect placebo effects or observer bias, so exenatide is not evidence of a cure. Exenatide phase 2a trial

Several earlier-stage approaches seek to repair the cellular damage that persists even if alpha-synuclein aggregation is reduced. In laboratory models, the thyroid-hormone-like compound sobetirome restored myelin-related proteins in oligodendrocytes burdened with alpha-synuclein, suggesting a possible remyelination strategy. Sobetirome and MSA demyelination RNA therapies, including antisense oligonucleotides that lower production of alpha-synuclein, have reduced alpha-synuclein pathology in animal synucleinopathy models, but they have not yet established safety or efficacy in an MSA clinical trial. Alpha-synuclein antisense therapy

Clinical Trials and Experimental Approaches

The key active late-stage trial is Lundbeck’s MASCOT study of amlenetug, a randomized, double-blind phase 3 trial that began in December 2024. It enrolled 401 participants and compares high-dose amlenetug, low-dose amlenetug, and placebo over a 72-week blinded period, followed by an optional extension; primary completion is estimated for February 2028. MASCOT phase 3 trial This is the most important current test of whether sustained anti-alpha-synuclein treatment can meaningfully alter MSA progression.

Alterity Therapeutics’ ATH434 phase 2 study enrolled 77 people with early MSA and completed in November 2024 after 12 months of treatment with one of two oral doses or placebo. ATH434 phase 2 trial Mayo Clinic is also conducting a randomized, double-blind adaptive study of a patient’s own adipose-derived mesenchymal stromal cells, delivered into cerebrospinal fluid, with completion listed for December 2026. Mayo autologous MSC trial An even earlier Chinese phase 1 study is testing stereotactic transplantation of induced-pluripotent-stem-cell-derived dopaminergic neural progenitors into the putamen of people with MSA-P; its planned enrollment is only three participants, so it is principally a safety study. XS411CN neural progenitor trial

Recent negative results are equally informative. Takeda’s phase 2 trial of the anti-alpha-synuclein antibody TAK-341/MEDI1341 enrolled 158 participants; after 52 weeks, mean modified UMSARS-Part I worsening was 5.1 points with TAK-341 and 5.2 with placebo, with no meaningful treatment difference. Takeda reported no further MSA studies planned for the program. TAK-341 phase 2 results

Methodologies and Scientific Approaches

MSA researchers combine patient studies with disease-relevant laboratory systems. These include transgenic mice that produce alpha-synuclein in oligodendrocytes, cell cultures of oligodendrocyte precursor cells, patient-derived cerebrospinal fluid, MRI measures of regional atrophy and iron, blood neurofilament light chain as a marker of nerve-cell injury, and digital gait measures. A newer rapidly progressive MSA-C mouse model reproduces oligodendrocyte alpha-synuclein accumulation, inflammation, demyelination, cerebellar dysfunction, and shortened survival, providing a more demanding platform for testing treatments before human trials. Rapid MSA-C mouse model

Biomarker development is central because MSA is often diagnosed after substantial degeneration has occurred. A multicenter 2024 study found that a cerebrospinal-fluid alpha-synuclein seed-amplification assay could identify MSA-associated “type 2” seeding patterns, with 87% sensitivity across MSA-enriched cohorts, although additional validation is needed before routine use. Multicenter synSAA study Earlier identification and biomarker-confirmed enrollment should reduce diagnostic mixing with Parkinson’s disease and make disease-modifying trials more sensitive. MDS diagnostic criteria

Leading Institutions and Funding

Important clinical and research contributors include University College London and associated UK centers, which led the exenatide trial; Vanderbilt University Medical Center and Alterity Therapeutics, which have collaborated on ATH434; Lundbeck, sponsor of the phase 3 MASCOT antibody trial; Takeda, which completed the TAK-341 program; and Mayo Clinic, sponsor of the intrathecal autologous mesenchymal stromal-cell trial. Exenatide phase 2a trial ATH434 phase 2 trial MASCOT phase 3 trial Mayo autologous MSC trial

Patient organizations also play an increasingly practical funding role. Mission MSA’s CURE-MSA program funds multicenter work in biomarker discovery, natural history, symptom management, and disease-modifying interventions, offering up to $100,000 per project over two years. Mission MSA CURE-MSA grants At the federal level, the National Institute of Neurological Disorders and Stroke has stated that its Parkinson’s research initiatives may include broader synucleinopathies, including MSA, when they inform disease mechanisms and therapeutic development. NINDS Udall research initiative

Strengths, Limitations, and Challenges

The field’s main strength is that it now targets plausible disease mechanisms rather than symptoms alone: alpha-synuclein aggregation and spread, glial dysfunction, iron-related oxidative stress, inflammation, demyelination, and neuronal loss. It also has better trial-enabling tools, including revised diagnostic criteria, fluid biomarkers, imaging, and objective mobility measures. MDS diagnostic criteria Multicenter synSAA study The move from small phase 2 studies to a 401-participant phase 3 antibody study is a meaningful sign of maturation. MASCOT phase 3 trial

The limitations are substantial. MSA progresses quickly, is biologically heterogeneous, and is difficult to diagnose early, which can dilute trial results by enrolling people at different stages or with an incorrect diagnosis. Practical guide to MSA The TAK-341 failure shows that achieving brain exposure and engaging alpha-synuclein does not automatically slow disability, while the exenatide trial shows why open-label symptom-scale improvements must be checked against blinded, objective biomarkers and functional outcomes. TAK-341 phase 2 results Exenatide phase 2a trial Cell and gene-based therapies face additional challenges of surgical or intrathecal delivery, manufacturing consistency, immune safety, cost, and the uncertainty of whether replacing cells can overcome the hostile disease environment.

Outlook and Future Directions

As of October 3, 2026, MSA is not close to a proven cure, but the field is closer to a decisive answer on disease modification than it was in 2020. The milestones to watch are the phase 3 MASCOT readout for amlenetug, reproducible and independently confirmed ATH434 results, objective biomarker changes that track with clinical benefit, outcomes from rigorous stem-cell trials, and validation of alpha-synuclein seed assays for early recruitment. A realistic near-term goal is a treatment that measurably slows progression when started early; a cure will likely require combination therapy that suppresses alpha-synuclein pathology while protecting or restoring myelin, glia, and vulnerable neural circuits. AMULET amlenetug trial MASCOT phase 3 trial

References

• Practical guide to MSA — Goh et al., 2023.
• Symptomatic care in MSA — Fanciulli et al., 2023.
• AMULET amlenetug trial — Shimohata et al., 2026.
• MASCOT phase 3 trial — ClinicalTrials.gov, 2026.
• ATH434 in an MSA mouse model — Finkelstein et al., 2021.
• ATH434 phase 2 trial — ClinicalTrials.gov, 2024.
• Exenatide phase 2a trial — Vijiaratnam et al., 2025.
• Sobetirome and MSA demyelination — Mészáros et al., 2024.
• Alpha-synuclein antisense therapy — Cole et al., 2021.
• Mayo autologous MSC trial — ClinicalTrials.gov, 2026.
• XS411CN neural progenitor trial — ClinicalTrials.gov, 2026.
• TAK-341 phase 2 results — UK Health Research Authority, 2026.
• Rapid MSA-C mouse model — Ueda et al., 2024.
• Multicenter synSAA study — Martínez-Valbuena et al., 2024.
• MDS diagnostic criteria — Wenning et al., 2022.
• Mission MSA CURE-MSA grants — Mission MSA, 2026.
• NINDS Udall research initiative — National Institute of Neurological Disorders and Stroke, 2024.